06628 TRANSCENTA-B
- 0.610
- +0.010+1.67%
TRANSCENTA-B News
TRANSCENTA-B (06628) announced the latest Business progress on its new LIV-1 ADCs for the antitumor effects in models of triple-negative breast cancer at the 2024 SABCS.
TRANSCENTA-B (06628) announced that the 2024 San Antonio Breast Cancer Symposium (SABCS)...
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Chuangsheng Group - B (06628.HK) repurchased 0.069 million shares on December 5th for 0.0497 million Hong Kong dollars.
On December 5th, Grayscale Group-B (06628.HK) announced that it spent 0.0497 million Hong Kong dollars to repurchase 0.069 million shares.
Chuangsheng Group-B (06628.HK) has seen the executive director, chairman and CEO Qian Xueming increase shareholding by 0.15 million shares.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on December 2, Glorious Resources (06628.HK) was acquired by executive director, chairman, and CEO Qian Xueming in the market on November 27-28, 2024, with an average price per share of HK$0.61-0.64, totaling 0.15 million shares, involving approximately HK$0.093 million. After the increase, Qian Xueming's latest shareholding number is 37.3505 million shares, and the shareholding ratio has risen from 8.52% to 8.56%.
On November 27, Chuangsheng Group-B (06628.HK) spent 0.0499 million Hong Kong dollars to repurchase 0.078 million shares.
Gelonghui November 27丨Chuangsheng Group-B (06628.HK) announced that on November 27, it spent 0.0499 million Hong Kong dollars to repurchase 0.078 million shares.
Chuangsheng Group - B (06628) spent approximately 0.0112 million Hong Kong dollars to repurchase 0.0145 million shares on November 21.
Chuangsheng Group-B (06628) announced that on November 21, 2024, approximately 0.0112 million Hong Kong dollars were spent to repurchase 1....
Chuangsheng Group - B (06628.HK) spent 0.05 million Hong Kong dollars to repurchase 0.064 million shares on November 20th.
Gelonghui, November 20丨Chuangsheng Group-B (06628.HK) announced that on November 20, it spent 0.05 million Hong Kong dollars to repurchase 0.064 million shares.
Chuang Sheng Group -B (06628.HK) spent 0.049 million Hong Kong dollars to repurchase 0.059 million shares on November 19th.
Gelonghui, November 19丨Chuangsheng Group-B (06628.HK) announced that on November 19, it spent 0.049 million HKD to repurchase 0.059 million shares, with a repurchase price of 0.83 HKD per share.
Chun Sheng Group-B (06628.HK): Announced at the ESMO 2024 Congress, the latest business progress of OSEMITAMAB (TST001) triplet therapy for the first-line treatment of inspiring efficacy data for gastric or gastroesophageal junction adenocarcinoma.
On September 19th, Changsheng Group-B (06628.HK) announced updated research data on the G-queue for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (TranStar102) using Osemitamab (TST001) in combination with Narulitinib and CAPOX. The data from this queue has consistently shown encouraging efficacy since its announcement at the ASCO 2024 conference. The study results showed that in patients with known levels of CLDN18.2 and PD-L1 expression, patients with high/medium expression of CLDN18.2 had a median progression-free survival (mPFS).
TRANSCENTA-B: 2024 INTERIM REPORT
On September 10th, Chong Sheng Group-B (06628.HK) spent 0.095 million Hong Kong dollars to repurchase 0.076 million shares.
GlueNet September 10th, Creatilon Group-B (06628.HK) announced that on September 10th, it spent 0.095 million Hong Kong dollars to repurchase 0.076 million shares.
Chuangsheng Group - B [06628] is currently trading at HKD 1.13, with a decrease of 11.72%.
As of 15:28, China Winner Group - B [06628] reported HK$1.13, down HK$0.15 or 11.72% from yesterday's closing price of HK$1.28. The trading volume was HK$0.0188 million. The highest price today was HK$1.25 and the lowest price was HK$1.13. Based on yesterday's closing price, the 10-day average price was HK$1.81 and the 50-day average price was HK$1.83. The current P/E ratio is -1.41 times and the 14-day strength index is 31.25.
Chuangsheng Group-B (06628.HK) cancelled 2.14 million shares on August 29th.
Gelonghui August 29th | Chuangsheng Group-B (06628.HK) announced that on August 29, 2024, the company cancelled 2.14 million shares repurchased.
Chuangsheng Group B (06628) issued 2.1996 million shares under the stock-based incentive plan.
Chuangsheng Group-B (06628) announced that it will issue shares in accordance with the company's stock-based incentive plan on August 29, 2024...
Press Release: Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results
Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results
Chuangsheng Group-B (06628): Xu Li was appointed as a non-executive director.
Chuangsheng Group-B (06628) announced that Dr. Xu Li (Dr. Xu) has been appointed as a non-executive director and auditor of the company...
Chuangsheng Group-B (06628) released its interim results, with a net loss of 0.134 billion yuan, a decrease of 43.73% year-on-year.
CSG Group-B (06628) has released its interim performance for the six months ended June 30, 2024, during which the group achieved...
Express News | Transcenta - Hy Loss RMB133.7 Mln
No Data
